Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eledon Pharmaceuticals ( (ELDN) ) has provided an update.
On December 30, 2025, Eledon Pharmaceuticals, Inc. entered into an exchange agreement with Coastlands Capital Partners LP under which Coastlands swapped 4,203,764 shares of Eledon common stock for a pre-funded warrant to purchase an equivalent number of common shares. The warrant, which carries a nominal $0.001 exercise price and is immediately exercisable, is structured with ownership caps that limit Coastlands and its affiliates to holding no more than 4.99% of Eledon’s outstanding common stock post-exercise, with the potential to increase this cap up to 19.99% in line with Nasdaq rules; the unregistered, exempt transaction closed on December 30, 2025 and effectively reshapes the investor’s stake while controlling potential dilution and concentration of ownership.
The most recent analyst rating on (ELDN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.
Spark’s Take on ELDN Stock
According to Spark, TipRanks’ AI Analyst, ELDN is a Neutral.
ELDN’s score is held down primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). A positive offset comes from encouraging Phase 2 trial results supporting Phase 3 progress, but valuation support is limited given negative earnings and no dividend yield.
To see Spark’s full report on ELDN stock, click here.
More about Eledon Pharmaceuticals
Average Trading Volume: 2,189,305
Technical Sentiment Signal: Sell
Current Market Cap: $113.4M
Find detailed analytics on ELDN stock on TipRanks’ Stock Analysis page.